LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | XMD11-50 | 1.11 | uM | LJP6 | 72 | hr | 1311 | 2613 | 4935 | 0.5297 | 0.4340 |
MDA-MB-231 | XMD11-50 | 3.33 | uM | LJP6 | 72 | hr | 1311 | 1905 | 4935 | 0.3859 | 0.2152 |
MDA-MB-231 | XMD11-50 | 10 | uM | LJP6 | 72 | hr | 1311 | 1367 | 4935 | 0.2771 | 0.0213 |
MDA-MB-231 | XMD11-85h | 0.04 | uM | LJP6 | 72 | hr | 1311 | 3815 | 4935 | 0.7730 | 0.7478 |
MDA-MB-231 | XMD11-85h | 0.12 | uM | LJP6 | 72 | hr | 1311 | 4668 | 4935 | 0.9455 | 0.9415 |
MDA-MB-231 | XMD11-85h | 0.37 | uM | LJP6 | 72 | hr | 1311 | 4551 | 4935 | 0.9222 | 0.9171 |
MDA-MB-231 | XMD11-85h | 1.11 | uM | LJP6 | 72 | hr | 1311 | 4500 | 4935 | 0.9115 | 0.9048 |
MDA-MB-231 | XMD11-85h | 3.33 | uM | LJP6 | 72 | hr | 1311 | 4256 | 4935 | 0.8623 | 0.8507 |
MDA-MB-231 | XMD11-85h | 10 | uM | LJP6 | 72 | hr | 1311 | 2457 | 4935 | 0.4980 | 0.3885 |
MDA-MB-231 | XMD16-144 | 0.04 | uM | LJP5 | 72 | hr | 1311 | 2681 | 5079 | 0.5281 | 0.4408 |
MDA-MB-231 | XMD16-144 | 0.12 | uM | LJP5 | 72 | hr | 1311 | 1577 | 5079 | 0.3105 | 0.0979 |
MDA-MB-231 | XMD16-144 | 0.37 | uM | LJP5 | 72 | hr | 1311 | 1665 | 5079 | 0.3279 | 0.1291 |
MDA-MB-231 | XMD16-144 | 1.11 | uM | LJP5 | 72 | hr | 1311 | 1633 | 5079 | 0.3218 | 0.1188 |
MDA-MB-231 | XMD16-144 | 3.33 | uM | LJP5 | 72 | hr | 1311 | 1531 | 5079 | 0.3016 | 0.0825 |
MDA-MB-231 | XMD16-144 | 10 | uM | LJP5 | 72 | hr | 1311 | 774 | 5079 | 0.1525 | -0.2374 |
MDA-MB-231 | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 1311 | 4853 | 5079 | 0.9555 | 0.9539 |
MDA-MB-231 | Erlotinib | 0.12 | uM | LJP5 | 72 | hr | 1311 | 4941 | 5079 | 0.9727 | 0.9717 |
MDA-MB-231 | Erlotinib | 0.37 | uM | LJP5 | 72 | hr | 1311 | 5018 | 5079 | 0.9880 | 0.9878 |
MDA-MB-231 | Erlotinib | 1.11 | uM | LJP5 | 72 | hr | 1311 | 5014 | 5079 | 0.9870 | 0.9865 |
MDA-MB-231 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 1311 | 4951 | 5079 | 0.9745 | 0.9733 |
MDA-MB-231 | Erlotinib | 10 | uM | LJP5 | 72 | hr | 1311 | 3708 | 5079 | 0.7302 | 0.7022 |
MDA-MB-231 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 1311 | 5117 | 4935 | 1.0370 | 1.0382 |
MDA-MB-231 | Gefitinib | 0.12 | uM | LJP6 | 72 | hr | 1311 | 5020 | 4935 | 1.0173 | 1.0172 |
MDA-MB-231 | Gefitinib | 0.37 | uM | LJP6 | 72 | hr | 1311 | 5011 | 4935 | 1.0156 | 1.0162 |
MDA-MB-231 | Gefitinib | 1.11 | uM | LJP6 | 72 | hr | 1311 | 4958 | 4935 | 1.0047 | 1.0042 |